Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis
Posted inHematology-Oncology news Oncology

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients.
Comparative Outcomes of Treosulfan- versus Busulfan-Based Clofarabine Reduced Intensity Conditioning Regimens in Adult Allogeneic Transplant for Myeloid Malignancies
Posted inHematology-Oncology news

Comparative Outcomes of Treosulfan- versus Busulfan-Based Clofarabine Reduced Intensity Conditioning Regimens in Adult Allogeneic Transplant for Myeloid Malignancies

This retrospective study compares treosulfan and busulfan combined with clofarabine as reduced intensity conditioning before allogeneic transplant in adults with myeloid malignancies, highlighting faster neutrophil recovery and improved survival metrics with treosulfan.
Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay
Posted inHematology-Oncology news Oncology

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay

This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay for measurable residual disease assessment in real-world settings.
ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants
Posted inHematology-Oncology news

ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants

A randomized pilot trial shows comparable survival and safety outcomes for anti-thymocyte globulin alone versus combined with post-transplant cyclophosphamide, supporting further phase III investigation for graft-versus-host disease prophylaxis in matched donor hematopoietic cell transplantation.